OBJECTIVE: This study assessed whether early levels of biomarkers measured in CSF within 24-h of severe TBI would improve the clinical prediction of 6-months mortality. METHODS: This prospective study conducted at two Level 1 Trauma Centers enrolled adults with severe TBI (GCS ≤8) requiring a ventriculostomy as well as control subjects. Ventricular CSF was sampled within 24-h of injury and analyzed for seven candidate biomarkers (UCH-L1, MAP-2, SBDP150, SBDP145, SBDP120, MBP, and S100B). The International Mission on Prognosis and Analysis of Clinical Trials in TBI (IMPACT) scores (Core, Extended, and Lab) were calculated for each patient to determine risk of 6-months mortality. The IMPACT models and biomarkers were assessed alone and in combination. RESULTS: There were 152 patients enrolled, 131 TBI patients and 21 control patients. Thirty six (27 %) patients did not survive to 6 months. Biomarkers were all significantly elevated in TBI versus controls (p < 0.001). Peak levels of UCH-L1, SBDP145, MAP-2, and MBP were significantly higher in non-survivors (p < 0.05). Of the seven biomarkers measured at 12-h post-injury MAP-2 (p = 0.004), UCH-L1 (p = 0.024), and MBP (p = 0.037) had significant unadjusted hazard ratios. Of the seven biomarkers measured at the earliest time within 24-h, MAP-2 (p = 0.002), UCH-L1 (p = 0.016), MBP (p = 0.021), and SBDP145 (0.029) had the most significant elevations. When the IMPACT Extended Model was combined with the biomarkers, MAP-2 contributed most significantly to the survival models with sensitivities of 97-100 %. CONCLUSIONS: These data suggest that early levels of MAP-2 in combination with clinical data provide enhanced prognostic capabilities for mortality at 6 months.
OBJECTIVE: This study assessed whether early levels of biomarkers measured in CSF within 24-h of severe TBI would improve the clinical prediction of 6-months mortality. METHODS: This prospective study conducted at two Level 1 Trauma Centers enrolled adults with severe TBI (GCS ≤8) requiring a ventriculostomy as well as control subjects. Ventricular CSF was sampled within 24-h of injury and analyzed for seven candidate biomarkers (UCH-L1, MAP-2, SBDP150, SBDP145, SBDP120, MBP, and S100B). The International Mission on Prognosis and Analysis of Clinical Trials in TBI (IMPACT) scores (Core, Extended, and Lab) were calculated for each patient to determine risk of 6-months mortality. The IMPACT models and biomarkers were assessed alone and in combination. RESULTS: There were 152 patients enrolled, 131 TBIpatients and 21 control patients. Thirty six (27 %) patients did not survive to 6 months. Biomarkers were all significantly elevated in TBI versus controls (p < 0.001). Peak levels of UCH-L1, SBDP145, MAP-2, and MBP were significantly higher in non-survivors (p < 0.05). Of the seven biomarkers measured at 12-h post-injury MAP-2 (p = 0.004), UCH-L1 (p = 0.024), and MBP (p = 0.037) had significant unadjusted hazard ratios. Of the seven biomarkers measured at the earliest time within 24-h, MAP-2 (p = 0.002), UCH-L1 (p = 0.016), MBP (p = 0.021), and SBDP145 (0.029) had the most significant elevations. When the IMPACT Extended Model was combined with the biomarkers, MAP-2 contributed most significantly to the survival models with sensitivities of 97-100 %. CONCLUSIONS: These data suggest that early levels of MAP-2 in combination with clinical data provide enhanced prognostic capabilities for mortality at 6 months.
Authors: P E Vos; B Jacobs; T M J C Andriessen; K J B Lamers; G F Borm; T Beems; M Edwards; C F Rosmalen; J L M Vissers Journal: Neurology Date: 2010-11-16 Impact factor: 9.910
Authors: Kevin K W Wang; Andrew K Ottens; Ming Cheng Liu; Stephen B Lewis; Colleen Meegan; Monika W Oli; Frank C Tortella; Ronald L Hayes Journal: Expert Rev Proteomics Date: 2005-08 Impact factor: 3.940
Authors: L M Ytrebø; G I Nedredal; C Korvald; O J Holm Nielsen; T Ingebrigtsen; B Romner; J Aarbakke; A Revhaug Journal: Scand J Clin Lab Invest Date: 2001-05 Impact factor: 1.713
Authors: Gretchen M Brophy; Stefania Mondello; Linda Papa; Steven A Robicsek; Andrea Gabrielli; Joseph Tepas; Andras Buki; Claudia Robertson; Frank C Tortella; Ronald L Hayes; Kevin K W Wang Journal: J Neurotrauma Date: 2011-04-08 Impact factor: 5.269
Authors: Ewout W Steyerberg; Nino Mushkudiani; Pablo Perel; Isabella Butcher; Juan Lu; Gillian S McHugh; Gordon D Murray; Anthony Marmarou; Ian Roberts; J Dik F Habbema; Andrew I R Maas Journal: PLoS Med Date: 2008-08-05 Impact factor: 11.069
Authors: Juan Pablo de Rivero Vaccari; Frank Brand; Stephanie Adamczak; Stephanie W Lee; Jon Perez-Barcena; Michael Y Wang; M Ross Bullock; W Dalton Dietrich; Robert W Keane Journal: J Neurochem Date: 2015-03-01 Impact factor: 5.372
Authors: Julia Halford; Sean Shen; Kyohei Itamura; Jaclynn Levine; Albert C Chong; Gregg Czerwieniec; Thomas C Glenn; David A Hovda; Paul Vespa; Ross Bullock; W Dalton Dietrich; Stefania Mondello; Joseph A Loo; Ina-Beate Wanner Journal: J Cereb Blood Flow Metab Date: 2017-08-17 Impact factor: 6.200
Authors: Michael Frankel; Liqiong Fan; Sharon D Yeatts; Andreas Jeromin; Pieter E Vos; Amy K Wagner; Bethany J Wolf; Qi Pauls; Michael Lunney; Lisa H Merck; Casey L Hall; Yuko Y Palesch; Robert Silbergleit; David W Wright Journal: J Neurotrauma Date: 2019-07-09 Impact factor: 5.269
Authors: Brian K Kwon; Ona Bloom; Ina-Beate Wanner; Armin Curt; Jan M Schwab; James Fawcett; Kevin K Wang Journal: Spinal Cord Date: 2019-07-04 Impact factor: 2.772
Authors: Linda Papa; Steven A Robicsek; Gretchen M Brophy; Kevin K W Wang; H Julia Hannay; Shelley Heaton; Ilona Schmalfuss; Andrea Gabrielli; Ronald L Hayes; Claudia S Robertson Journal: J Neurotrauma Date: 2017-11-03 Impact factor: 5.269
Authors: Frederick Korley; Qi Pauls; Sharon D Yeatts; Courtney Marie Cora Jones; Emily Corbett-Valade; Robert Silbergleit; Michael Frankel; William Barsan; Nathan D Cahill; Jeffrey J Bazarian; David W Wright Journal: J Neurotrauma Date: 2021-01-25 Impact factor: 4.869
Authors: Taylor N Anderson; Jun Hwang; Myrna Munar; Linda Papa; Holly E Hinson; Allison Vaughan; Susan E Rowell Journal: J Trauma Acute Care Surg Date: 2020-07 Impact factor: 3.697